|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Clinical Neuro-Oncology |
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143-0112, USA
2 Address correspondence to Kathleen R. Lamborn, Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Avenue, San Francisco, CA 94143-0372 (lambornk{at}neurosurg.ucsf.edu).
Abstract
Survival for patients with glioblastoma multiforme is short, and current treatments provide limited benefit. Therefore, there is interest in conducting phase 2 trials of experimental treatments in newly diagnosed patients. However, this requires historical data with which to compare the experimental therapies. Knowledge of prognostic markers would also allow stratification into risk groups for phase 3 randomized trials. In this retrospective study of 832 glioblastoma multiforme patients enrolled into prospective clinical trials at the time of initial diagnosis, we evaluated several potential prognostic markers for survival to establish risk groups. Analyses were done using both Cox proportional hazards modeling and recursive partitioning analyses. Initially, patients from 8 clinical trials, 6 of which included adjuvant chemotherapy, were included. Subsequent analyses excluded trials with interstitial brachytherapy, and finally included only nonbrachytherapy trials with planned adjuvant chemotherapy. The initial analysis defined 4 risk groups. The 2 lower risk groups included patients under the age of 40, the lowest risk group being young patients with tumor in the frontal lobe only. An intermediate-risk group included patients with Karnofsky performance status (KPS) >70, subtotal or total resection, and age between 40 and 65. The highest risk group included all patients over 65 and patients between 40 and 65 with either KPS < 80 or biopsy only. Subgroup analyses indicated that inclusion of adjuvant chemotherapy provides an increase in survival, although that improvement tends to be minimal for patients over age 65, for patients over age 40 with KPS less than 80, and for those treated with brachytherapy.
References
Breiman, L., Friedman, J.H., Olshen, R.A., and Stone, C.J. (1984) Classification and Regression Trees. Belmont, Calif.: Wadsworth International Group.
Curran, W.J., Jr., Scott, C.B., Horton, J., Nelson, J.S.,
Weinstein, A.S., Fischbach, A.J., Chang, C.H., Rotman, M., Asbell, S.O.,
Krisch, R.E., and Nelson, D.F. (1993) Recursive partitioning
analysis of prognostic factors in three Radiation Therapy Oncology Group
malignant glioma trials. J. Natl. Cancer Inst.
85,704
-710.
GMT. Glioma Meta-analysis Trialists (GMT) Group (2002) Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359,1011 -1018.[CrossRef][Web of Science][Medline]
Keles, S., and Segal, M.R. (2002) Residual-based tree-structured survival analysis. Stat. Med. 21,313 -326.[CrossRef][Web of Science][Medline]
Laperriere, N.J., Leung, P.M.K., McKenzie, S., Milosevic, M., Wong, S., Glen, J., Pintilie, M., and Bernstein, M. (1998) Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 41,1005 -1011.[CrossRef][Web of Science][Medline]
Schmoor, C., Ulm, K., and Schumacher, M. (1993) Comparison of the Cox model and the regression tree procedure in analysing a randomized clinical trial. Stat. Med. 12,2351 -2366.[Web of Science][Medline]
Selker, R.G., Shapiro, W.R., Burger, P., Blackwood, M.S., Deutsch, M., Arena, V.C., Van Gilder, J.C., Wu, J., Malkin, M.G., Mealey, J., Jr., Neal, J.H., Olson, J., Robertson, J.T., Barnett, G.H., Bloomfield, S., Albright, R., Hochberg, F.H., Hiesiger, E., Green S., and Brain Tumor Cooperative Group (2002) The Brain Tumor Cooperative Group NIH trial 87-01: A randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51,343 -357.[Web of Science][Medline]
Therneau, T.M., Grambsch, P.M., and Fleming, T.R.
(1990) Martingale-based residuals for survival models.
Biometrika 77,147
-160.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Lai, D. L. Hershman, T. Doan, and A. I. Neugut The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme Neuro Oncology, October 15, 2009; (2009) nop004v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Pichlmeier, A. Bink, G. Schackert, W. Stummer, and the ALA Glioma Study Group Resection and survival in glioblastoma multiforme: An RTOG recursive partitioning analysis of ALA study patients Neuro-oncol, January 1, 2008; 10(6): 1025 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Lim, S. Cha, M. C. Mayo, M.-H. Chen, E. Keles, S. VandenBerg, and M. S. Berger Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype Neuro-oncol, October 1, 2007; 9(4): 424 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Carson, S. A. Grossman, J. D. Fisher, and E. G. Shaw Prognostic Factors for Survival in Adult Patients With Recurrent Glioma Enrolled Onto the New Approaches to Brain Tumor Therapy CNS Consortium Phase I and II Clinical Trials J. Clin. Oncol., June 20, 2007; 25(18): 2601 - 2606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Mamelak, S. Rosenfeld, R. Bucholz, A. Raubitschek, L. B. Nabors, J. B. Fiveash, S. Shen, M.B. Khazaeli, D. Colcher, A. Liu, et al. Phase I Single-Dose Study of Intracavitary-Administered Iodine-131-TM-601 in Adults With Recurrent High-Grade Glioma J. Clin. Oncol., August 1, 2006; 24(22): 3644 - 3650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.-O. Mirimanoff, T. Gorlia, W. Mason, M. J. Van den Bent, R.-D. Kortmann, B. Fisher, M. Reni, A. A. Brandes, J. Curschmann, S. Villa, et al. Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial J. Clin. Oncol., June 1, 2006; 24(16): 2563 - 2569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wrensch, J. K. Wiencke, J. Wiemels, R. Miike, J. Patoka, M. Moghadassi, A. McMillan, K. T. Kelsey, K. Aldape, K. R. Lamborn, et al. Serum IgE, Tumor Epidermal Growth Factor Receptor Expression, and Inherited Polymorphisms Associated with Glioma Survival. Cancer Res., April 15, 2006; 66(8): 4531 - 4541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wrensch, T. Rice, R. Miike, A. McMillan, K. R. Lamborn, K. Aldape, and M. D. Prados Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area Neuro-oncol, January 1, 2006; 8(1): 12 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Chang, S. L. Reynolds, N. Butowski, K. R. Lamborn, J. C. Buckner, R. S. Kaplan, and D. D. Bigner GNOSIS: Guidelines for neuro-oncology: Standards for investigational studies--reporting of phase 1 and phase 2 clinical trials Neuro-oncol, October 1, 2005; 7(4): 425 - 434. [Abstract] [PDF]
|
|
|
|
|
|
J. N. Rich, C. Hans, B. Jones, E. S. Iversen, R. E. McLendon, B.K. A. Rasheed, A. Dobra, H. K. Dressman, D. D. Bigner, J. R. Nevins, et al. Gene Expression Profiling and Genetic Markers in Glioblastoma Survival Cancer Res., May 15, 2005; 65(10): 4051 - 4058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Misra, M. Pellarin, J. Nigro, I. Smirnov, D. Moore, K. R. Lamborn, D. Pinkel, D. G. Albertson, and B. G. Feuerstein Array Comparative Genomic Hybridization Identifies Genetic Subgroups in Grade 4 Human Astrocytoma Clin. Cancer Res., April 15, 2005; 11(8): 2907 - 2918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Moffat, T. L. Chenevert, T. S. Lawrence, C. R. Meyer, T. D. Johnson, Q. Dong, C. Tsien, S. Mukherji, D. J. Quint, S. S. Gebarski, et al. Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response PNAS, April 12, 2005; 102(15): 5524 - 5529. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
